9月22日 - ** Compass Therapeutics（CMPX.O）股价在盘前交易中下跌40.8%，至1.51美元
** 该公司表示，美国食品药品监督管理局（FDA）建议在为其实验性药物托维西米格（tovecimig）提交上市申请前，先进行一项新试验以证明该药对生存期的获益
** Tovecimig 目前正在晚期胆道癌患者中进行临床试验，这是一种起源于胆管或胆囊的罕见且侵袭性强的恶性肿瘤
** 基于其中期至后期临床试验结果以及患者迫切未满足的医疗需求，Compass表示认为在提交上市申请前无需进行新的临床试验
** 该公司表示，计划与美国食品药品监督管理局（FDA）进一步沟通
** 截至上一交易日收盘，该公司股票今年以来累计下跌66%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.